UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2022

Dermata Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**001-40739**	**86-3218736**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3525 Del Mar Heights Rd., #322
San Diego, CA 92130
(Address of principal executive offices, including zip code)

(858) 800-2543
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:	**Trading Symbol**	**Name of Each Exchange on which Registered**
Common Stock, par value $0.0001 per share	DRMA	The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock	DRMAW	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 (Other Events).

Dermata Therapeutics, Inc. (the "Company") received correspondence from the U.S. Food and Drug Administration (the "FDA") regarding the Company's submitted waiver request for the requirements to complete a 90-day dermal toxicity minipig study and a standard pharmacokinetic ("PK") study prior to holding an End of Phase 2 meeting with the FDA for the Company's DMT310 acne program. The FDA has confirmed the Company should complete a 90-day dermal minipig study and PK study prior to initiating the Phase 3 acne program. The FDA agreed with the dosing and treatment timeline proposed by the Company for the 90-day dermal minipig study. The Company plans to initiate the 90-day dermal minipig study in the first half of 2022. Accordingly, the Company plans to request an End of Phase 2 meeting with the FDA in the first half of 2023 and begin the Phase 3 acne program in the first half of 2023. The FDA also informed the Company that the requirement to conduct certain pharmacology studies and systemic toxicity studies may be waived if the Company can demonstrate limited systemic exposure of DMT310 in the minipig and PK studies.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DERMATA THERAPEUTICS, INC.

Dated: March 2, 2022

By: */s/ Gerald T. Proehl*
Gerald T. Proehl
Chief Executive Officer